risedronic acid monosodium salt hemipentahydrate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机膦酸及其衍生物
• 英文名称: risedronic acid monosodium salt hemipentahydrate
• 英文别名: hemi-pentahydrate monosodium salt of [1-hydroxy-2-(3-pyridinyl)ethylidene]bisphosphonic acid.；[1-hydroxy-2-(3-pyridinyl)ethylidene]bisphosphonic acid monosodium salt hemipentahydrate；[1-hydroxy-2-(3-pyridinyl)ethylidene]bis(phosphonic acid) monosodium hemi-pentahydrate；3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium salt hemipentahydrate；monosodium 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonate hemipentahydrate；risedronate monosodium hemipentahydrate；Sodium;(1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid;hydroxide；sodium;(1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid;hydroxide
• 化学式: C₇H₁₀NO₇P₂*2H₂O*Na
• 分子量: 350.134
• InChiKey: KLQNARDFMJRXSF-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -4.83
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  152
• 氢给体数：
  5
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  risedronic acid monosodium salt hemipentahydrate 以 甲醇 为溶剂， 反应 12.0h， 以96.4%的产率得到Risedronate
  参考文献：
  名称：

  [EN] PROCESS FOR PREPARING RISEDRONATE SODIUM AS ANHYDROUS AND HYDRATE FORMS
  [FR] PROCÉDÉ DE PRÉPARATION DE RISÉDRONATE DE SODIUM COMME FORMES ANHYDRES ET HYDRATÉES

  摘要：

  公开号：

  WO2009072769A3
• 作为产物：
  描述：

  利塞膦酸 在 sodium hydroxide 、 水 作用下， 以 异丙醇 为溶剂， 反应 4.0h， 生成 risedronic acid monosodium salt hemipentahydrate
  参考文献：
  名称：

  [EN] A NEW CRYSTALLINE FORM OF THE SODIUM SALT OF 3-PYRIDYL-1-HYDROXYETHYLIDENE-1,1-BISPHOSPHONIC ACID
  [FR] NOUVELLE FORME CRISTALLINE DE SEL DE SODIUM D'ACIDE 3-PYRIDYL-1-HYDROXYETHYLIDENE-1,1-BIPHOSPHONIQUE

  摘要：

  一种结晶的、水合的3-吡啶基-1-羟乙基亚甲基-1，1-双膦酸钠盐含有6.4%至22%的钠，基于无水物质，并且如果钠的含量低于7.5%则含有15%至23%的结晶水，如果钠的含量高于7.5%，则含有4.5%至18%的结晶水。

  公开号：

  WO2004037252A1

文献信息

• Process for the preparation of risedronate sodium hemi-pentahydrate
  申请人：Divvela Srinivasa Rao V.N

  公开号：US20070173484A1

  公开（公告）日：2007-07-26

  The present invention relates to an improved process for the selective crystallization of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium in pure hemi-pentahydrate form of Formula (I), by first converting 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid into organic amine salt and then by replacing it with sodium salt.

  本发明涉及一种改进的工艺，用于将3-吡啶基-1-羟乙基亚甲基-1,1-双磷酸钠有选择地结晶成纯的半五水合物形式（化学式（I）），首先将3-吡啶基-1-羟乙基亚甲基-1,1-双磷酸转化为有机胺盐，然后再用钠盐替换。
• [EN] IMPROVED PROCESS FOR THE PREPARATION OF RISEDRONATE SODIUM HEMIPENTAHYDRATE<br/>[FR] PROCÉDÉ AMÉLIORÉ DE PRÉPARATION DE RISÉDRONATE MONOSODIQUE HÉMIPENTAHYDRATÉ
  申请人：FLEMING LAB LTD

  公开号：WO2009034580A1

  公开（公告）日：2009-03-19

  The invention relates to the process of preparation of Risedronic acid and Risedronate sodium hemipentahydrate in the absence of organic solvents. The process comprises, reacting 3-pyridyl acetic acid with phosphorous acid and phosphorus trichloride to give Risedronic acid which is further reacted with sodium hydroxide in water medium to give Risedronate sodium hemipentahydrate.

  本发明涉及在无机溶剂的情况下制备瑞舒地酸和瑞舒特纳钠半五水合物的过程。该过程包括将3-吡啶乙酸与磷酸和三氯化磷反应，得到瑞舒地酸，然后在水介质中将其与氢氧化钠反应，得到瑞舒特纳钠半五水合物。
• Process of Making Geminal Bisphosphonic Acids and Pharmaceutically Acceptable Salts and/or Hydrates Thereof
  申请人：Serrano Jordi Puig

  公开号：US20080194525A1

  公开（公告）日：2008-08-14

  This invention relates to the process of making geminal bisphosphonic acids and pharmaceutically acceptable salts and/or hydrates thereof which have the formula (I): wherein X 1 , X 2 , X 3 , X 1 R 1 and R 2 are described herein.

  本发明涉及制备双醇基双膦酸及其药学上可接受的盐和/或水合物的过程，其化学式为(I)：其中X1、X2、X3、X1R1和R2如本文所述。
• Method for preparing crystalline sodium risedronate
  申请人：Sandoz A/S

  公开号：EP1775302A1

  公开（公告）日：2007-04-18

  A new procedure for preparing crystalline sodium risedronate is disclosed, which procedure takes place under conditions where the availability of water is strictly limited. New sodium risedronate forms prepared according to the new procedure are also disclosed. The new sodium risedronate forms are useful for the preparation of pharmaceutical compositions for the treatment of diseases of bone and calcium metabolism.

  本发明公开了一种制备晶体硼酸钠的新工艺，该工艺在水的可用性严格受限的条件下进行。还公开了根据新工艺制备的新型硼酸钠形式。这些新型硼酸钠形式可用于制备用于治疗骨骼和钙代谢疾病的药物组合物。
• Diketohydrazine derivative compounds and drugs contaiing the compounds as the active ingredient
  申请人：Hatayama Akira

  公开号：US20060111303A1

  公开（公告）日：2006-05-25

  The present invention relates to a diketohydrazine derivative of formula (I) and a pharmaceutically acceptable salt thereof (the symbols in the formula have the same meaning as described in the specification). The compound of formula (I) has an inhibitory activity against cysteine protease, and it is useful for the treatment of inflammatory diseases, immune diseases, ischemic diseases, respiratory diseases, circulatory diseases, blood diseases, neuronal diseases, hepatic or biliary diseases, osseous or articular diseases, metabolic diseases, etc. And the compound has inhibitory activity against elastase and it is also useful for the treatment of COPD (chronic obstacle pulmonary diseases).

  本发明涉及一种公式（I）的二酮肼衍生物及其药学上可接受的盐（公式中的符号与说明书中描述的含义相同）。公式（I）的化合物具有对半胱氨酸蛋白酶的抑制活性，可用于治疗炎症性疾病、免疫性疾病、缺血性疾病、呼吸系统疾病、循环系统疾病、血液疾病、神经系统疾病、肝胆系统疾病、骨骼或关节疾病、代谢性疾病等。该化合物具有对弹性蛋白酶的抑制活性，也可用于慢性阻塞性肺疾病（COPD）的治疗。